Model‡ | Comorbidity count* | Age† | Sex† | ||||||
No | Odds ratio (95% CrI) | Bayesian P value | No | Odds ratio (95% CrI) | Bayesian P value | No | Odds ratio (95% CrI) | Bayesian P value | |
Pooled (ignoring drug class and index condition) | n=89 trials | 1.11 (1.07 to 1.14) | 1.00 | n=90 trials | 1.04 (0.98 to 1.11) | 0.89 | n=83 trials | 0.99 (0.93 to 1.05) | 0.32 |
SD trial | 0.10 | — | — | 0.22 | — | — | 0.13 | — | — |
Partial pooling across index conditions | n=20 index conditions | 1.11 (1.06 to 1.15) | 1.00 | n=20 index conditions | 1.06 (0.97 to 1.20) | 0.89 | n=18 index conditions | 0.99 (0.90 to 1.11) | 0.41 |
SD trial | 0.09 | — | — | 0.21 | — | — | 0.11 | — | — |
SD index condition | 0.05 | — | — | 0.09 | — | — | 0.12 | — | — |
Partial pooling across drug classes | n=17 drug classes | 1.09 (1.05 to 1.15) | 1.00 | n=17 drug classes | 1.04 (0.97 to 1.13) | 0.86 | n=17 drug classes | 1.00 (0.92 to 1.11) | 0.50 |
SD trial | 0.10 | — | — | 0.22 | — | — | 0.09 | — | — |
SD drug class | 0.04 | — | — | 0.07 | — | — | 0.11 | — | — |
Partial pooling across index conditions and drug class | n=20 index conditions; n=17 drug classes | 1.11 (1.05 to 1.15) | 1.00 | n=20 index conditions; n=17 drug classes | 1.05 (0.96 to 1.16) | 0.89 | n=18 index conditions; n=17 drug classes | 1.00 (0.90 to 1.12) | 0.49 |
SD trial | 0.09 | — | — | 0.21 | — | — | 0.09 | — | — |
SD index condition | 0.04 | — | — | 0.09 | — | — | 0.09 | — | — |
SD drug class | 0.04 | — | — | 0.07 | — | — | 0.09 | — | — |
CrI=credible interval; SD=standard deviation.
*Trial level models adjusted for age, sex, and comorbidity count.
†Trial level models adjusted for age and sex. Bayesian P value to describe proportion of distribution above odds ratio of 1. See online supplemental appendix for full description of models.
‡Standard deviation for variation within groups for trials, index conditions, and drug classes on log-odds scale.